Enlivex Therapeutics Ltd. (ENLV) Granted Two US Patents Covering Methods of Treating Sepsis with Allocetra
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2022
- S&P 500, Nasdaq close up 4th straight week as optimism grows
- 'Back in Tech': Investors are Increasing Exposure to Tech and Growth Stocks - BofA
- Rivian Reports Bigger Loss, Says Current Models Won't Qualify for Tax Breaks
- US-listed China Stocks Slip on Delisting Moves, Analyst Sees Short-term Noise
- Salesforce (CRM), Snowflake (SNOW) Rated New Sell at Guggenheim, Oracle (ORCL) at Buy
- 3M (MMM) Commences Split-Off Exchange Offer for Food Safety Business
- Repligen (RGEN) Has Rejected an Initial Takeover Offer from Catalent (CTLT) - Source
- Forza X1, Inc. (FRZA) Prices 3M Share IPO at $5/sh
- What Will Happen to Ethereum (ETH) Miners Post the Merge? JPMorgan Looks at Options
- Canadian Solar's (CSIQ) Subsidiary CSI Solar Plans to Build Approximately 50,000 Tons of High-Purity Polysilicon of Annual Capacity in Qinghai, China
- Pre-Open Movers: Small-cap UNITY Bio Climbs 110%, Alibaba Declines
- After-Hours Movers: Rivian Edges Slightly Higher, Illumina Tanks
- Pre-Open Movers: Disney Surges After Subscriber Adds Beat, Six Flags Shares Fall
- Companies with NDRs 8/11
- After-Hours Movers: Disney Climbs After Adding Subscribers, Sonos Sinks
Enlivex Announces Issuance of Two U.S. Patents Covering Methods of Treating Sepsis with Allocetra
May 5, 2022 8:37 AM EDTNes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the Company), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each patent provides Enlivex with added intellectual property (IP) protection in the United States until at least 2036 with respect to claims covering methods of treating sepsis with AllocetraTM. Â
Oren Hershkovitz, PhD, CEO of Enlivex, stated, These latest patents add important depth to the IP portfolio protecting our sepsis program, with one specifically covering the treatment of sepsis derived from pneumonia, urinary, or biliary tract infections. These are three important... More
